Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 open-label extension in adults with focal seizures
ACTRN12616001455459Phase 2Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Nov 2016
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Zygel in epilepsy and Focal onset seizure, sponsored by Zynerba Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of ZYN002. Started Nov 2016; status: completed.
02
Drugs
Zygel
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on ACTRN12616001455459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001455459.